AYTU - Company ID 0001385818
The table below shows AYTU BIOPHARMA, INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $12.41M | $15.16M | $13.89M | $18.45M | $16.22M | $16.57M |
| Cost of revenue | $4.81M | $5.54M | $4.70M | $5.65M | $5.43M | $4.59M |
| Gross profit | $7.60M | $9.62M | $9.19M | $12.81M | $10.79M | $11.98M |
| R&D | $0.00 | $0.00 | $0.00 | $162.00K | $522.00K | $426.00K |
AYTU BIOPHARMA, INC reported annual revenue of $66.38M for fiscal year 2025. That is up 1.8% from $65.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $2.56M (FY 2016) to $66.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $4.97M | $5.07M | $4.92M | $4.11M | $4.45M | $5.13M |
| Operating income | -$4.06M | -$1.97M | -$1.50M | $2.42M | -$1.70M | -$930.00K |
| Income tax | $10.00K | $0.00 | $0.00 | -$122.00K | -$283.00K | $405.00K |
| Net income | -$5.62M | -$10.58M | $1.97M | $3.99M | $788.00K | $1.47M |
| EPS (diluted) | -$0.53 | -$1.05 | -$0.08 | $0.21 | -$0.26 | -$0.15 |